Manages OA 1.2 Rheumatoid Arthritis (RA). ANDA 207872, held by Tianjin Tianyao. Celecoxib.
As of Nov 15, 2026, ANDA 207872 (Celecoxib), held by Tianjin Tianyao, was first approved by FDA on Feb 25, 2020, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Celecoxib capsules is indicated Celecoxib capsules is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2020 | Original application | Approved | None posted |
| Jul 16, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 25, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters